Real‐world impact of direct acting antiviral therapy on health‐related quality of life in HIV/Hepatitis C co‐infected individuals. Issue 12 (27th September 2018)

• Record Type: Journal Article
• Authors: Saeed, Sahar; Moodie, Erica E. M.; Strumpf, Erin; Gill, John; Wong, Alexander; Cooper, Curtis; Walmsley, Sharon; Hull, Mark; Martel‐Laferriere, Valerie; Klein, Marina B.
• Other Names: Barrett Lisa investigator.; Cohen Jeff investigator.; Conway Brian investigator.; Côté Pierre investigator.; Cox Joseph investigator.; Haider Shariq investigator.; Pick Neora investigator.; Rachlis Anita investigator.; Rouleau Danielle investigator.; Sadr Aida investigator.; Tyndall Mark investigator.; Sanche Steve investigator.; Vachon Marie‐Louise investigator.
• Is Part Of: Journal of viral hepatitis. Volume 25:Issue 12(2018)
• Page Start: 1507
• Page End: 1514
• Publication Date: 2018-09-27
• Subjects: direct acting antivirals -- EQ‐5D -- health‐related quality of life -- hepatitis C -- HIV; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12985
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: Clinical trial results of direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) have shown improvements in health‐related quality of life (HR‐QoL). However, the extent to which these results are broadly generalizable to real‐world settings is unknown. We investigated the real‐world impact of oral DAA therapy on HR‐QoL among individuals coinfected with HIV/HCV. We used data from the Canadian HIV/HCV Co‐Infection Cohort Study that prospectively follows 1795 participants from 18 centres. Since 2007, clinical, lifestyle, and HR‐QoL data have been collected biannually through self‐administered questionnaires and chart review. HR‐QoL was measured using the EQ‐5D instrument. Participants initiating oral DAAs, having at least one visit before treatment initiation and at least one visit after DAA treatment response was ascertained, were included. Successful treatment response was defined as a sustained viral response (SVR). Segmented multivariate linear mixed models were used to evaluate the impact of SVR on HR‐QoL, controlling for pretreatment trends. 227 participants met our eligibility criteria, 93% of whom achieved SVR. Before treatment, the EQ‐5D utility index decreased 0.6 percentage‐point/y (95% CI, −0.9, −0.3) and health state was constant over time. The immediate effect of SVR resulted in an increase of 2.3‐units (−0.1, 4.7) in patients' health state and 2.0 percentage‐point increase (−0.2, 4.0) in utility index. Health state continued to increase post‐SVR by 1.4 units/y (−0.9, 3.7), while utility trends post‐SVR plateaued over the observation period. Overall using real‐world data, we found modest improvements in HR‐QoL following SVR, compared to previously published clinical trials.